Sign In
Buy ZVRA
$13.00
+0.350 (+2.77%)
At Close: Jun 23, 2026
Zevra Therapeutics to Participate in the Cantor Global Healthcare Conference
07:30am, Wednesday, 20'th Sep 2023
CELEBRATION, Fla., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that executive management
Zevra Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
07:30am, Tuesday, 05'th Sep 2023
CELEBRATION, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that executive management
Zevra's Rare Find: Unearthing Value In Niche Rare Diseases The Market Overlooks
01:30am, Tuesday, 05'th Sep 2023
Zevra's acquisition of Acer Therapeutics adds significant value to its rare disease-focused strategy. Acer's newly launched product, Olpruva, aligns with Zevra's potential commercial efforts with arim
How Much Upside is Left in Zevra Therapeutics (ZVRA)? Wall Street Analysts Think 248.51%
11:16am, Monday, 04'th Sep 2023
The consensus price target hints at a 248.5% upside potential for Zevra Therapeutics (ZVRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin
Zevra Therapeutics to Report Second Quarter 2023 Results on August 14, 2023
07:30am, Wednesday, 02'nd Aug 2023
CELEBRATION, Fla., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that
Zevra Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest
07:30am, Tuesday, 13'th Jun 2023
CELEBRATION, Fla., June 13, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, today announced ex
Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates
06:59pm, Monday, 15'th May 2023
Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.06 per share a year ago.
Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference on May 16, 2023
07:30am, Wednesday, 10'th May 2023
CELEBRATION, Fla., May 10, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, tod
Zevra Therapeutics to Report First Quarter 2023 Results on May 15, 2023
07:30am, Tuesday, 09'th May 2023
CELEBRATION, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that
Zevra Therapeutics, Inc. (ZVRA) Q4 2022 Earnings Call Transcript
03:24pm, Friday, 10'th Mar 2023
Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET Company Participants Nichol Ochsner - Vice President of Investor Relations Richard Pascoe - CEO LaDuan
Zevra Therapeutics to Present at 35th Annual Roth Conference
07:30am, Monday, 06'th Mar 2023
CELEBRATION, Fla., March 06, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, tod
